![GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrneph.2017.123/MediaObjects/41581_2017_Article_BFnrneph2017123_Fig1_HTML.jpg)
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology
![Structures of native GLP-1, exenatide, and liraglutide. The N-terminal... | Download Scientific Diagram Structures of native GLP-1, exenatide, and liraglutide. The N-terminal... | Download Scientific Diagram](https://www.researchgate.net/publication/41422599/figure/fig1/AS:340552282329093@1458205399850/Structures-of-native-GLP-1-exenatide-and-liraglutide-The-N-terminal-dipeptide-HA_Q640.jpg)
Structures of native GLP-1, exenatide, and liraglutide. The N-terminal... | Download Scientific Diagram
![Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in: Journal of Endocrinology Volume 236 Issue 1 (2018) Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in: Journal of Endocrinology Volume 236 Issue 1 (2018)](https://joe.bioscientifica.com/view/journals/joe/236/1/images/JOE-17-0278fig1.jpeg)
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in: Journal of Endocrinology Volume 236 Issue 1 (2018)
![Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes - ScienceDirect Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0167011503002696-gr2.gif)
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes - ScienceDirect
![Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force | SpringerLink Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13300-019-0669-4/MediaObjects/13300_2019_669_Fig3_HTML.png)
Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force | SpringerLink
![The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action - ScienceDirect The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1359644616300010-gr1.jpg)
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action - ScienceDirect
![Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41581-020-00367-2/MediaObjects/41581_2020_367_Fig1_HTML.png)
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology
![A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 - Czech - 2018 - Hepatology A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 - Czech - 2018 - Hepatology](https://aasldpubs.onlinelibrary.wiley.com/cms/asset/3058b433-f18e-43c8-9d5a-12ccc309c921/hep41147-fig-0001-m.jpg)
A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 - Czech - 2018 - Hepatology
![Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control | Hypertension Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control | Hypertension](https://www.ahajournals.org/cms/asset/8413f170-eb3f-4766-9e6c-b7a4552604a6/hypertensionaha.120.14868.fig07.jpg)
Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control | Hypertension
![Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists | Cardiovascular Diabetology | Full Text Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-014-0142-7/MediaObjects/12933_2014_Article_142_Fig1_HTML.jpg)
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists | Cardiovascular Diabetology | Full Text
![Neurotrophic effects of exenatide is mediated by TrkB signalling in... | Download Scientific Diagram Neurotrophic effects of exenatide is mediated by TrkB signalling in... | Download Scientific Diagram](https://www.researchgate.net/profile/Alberto-Granzotto/publication/321911284/figure/fig1/AS:579113670516736@1515082866820/Neurotrophic-effects-of-exenatide-is-mediated-by-TrkB-signalling-in-vitro-A.png)
Neurotrophic effects of exenatide is mediated by TrkB signalling in... | Download Scientific Diagram
![Hypothalamic Insulin-Sensitizing Effect of Exenatide in Dietary Induced Rat Model of Obesity | Bentham Science Hypothalamic Insulin-Sensitizing Effect of Exenatide in Dietary Induced Rat Model of Obesity | Bentham Science](https://www.eurekaselect.com/images/graphical-abstract/cdth/12/1/006.jpg)
Hypothalamic Insulin-Sensitizing Effect of Exenatide in Dietary Induced Rat Model of Obesity | Bentham Science
![Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. - Abstract - Europe PMC Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6739887/bin/xce-7-18-g001.jpg)